Patents Assigned to Visterra, Inc.
  • Antibody molecule-drug conjugates and uses thereof
    Patent number: 11969476
    Abstract: Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: April 30, 2024
    Assignee: VISTERRA, INC.
    Inventors: Karthik Viswanathan, Kenneth Douglas Johnson, Obadiah Joseph Plante, James C. Delaney, Tyree J. Koch, Hamid Tissire, Andrew M. Wollacott, Boopathy Ramakrishnan
  • TREATMENT OF COMPLEMENT MEDIATED DISEASES AND DISORDERS WITH C3B ANTIBODIES
    Publication number: 20240132617
    Abstract: The present invention provides, among other things, anti-C3b antibodies with increased specificity and potency and methods of treating C3 glomerulopathy and other complement mediated diseases and disorders using the same.
    Type: Application
    Filed: September 19, 2023
    Publication date: April 25, 2024
    Applicant: Visterra, Inc.
    Inventors: Karthik Viswanathan, Ramki Ramakrishnan, Hedy Adari, Feng Gao, Andrew Wollacott
  • Antibody molecules to CD138 and uses thereof
    Patent number: 11945868
    Abstract: Antibody molecules that specifically bind to CD138 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: April 2, 2024
    Assignee: VISTERRA, INC.
    Inventors: Bharat Chaganty, Boopathy Ramakrishnan, Hedy Adari-Hall, Karthik Viswanathan, James R. Myette, Zachary Shriver
  • Formulations of antibody molecules to dengue virus
    Patent number: 11918651
    Abstract: Formulations of peptide agents, such as antibodies and antigen-binding fragments thereof, that bind dengue viruses, and methods of their use, are provided.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: March 5, 2024
    Assignee: VISTERRA, INC.
    Inventors: Catherine Hay, Susan Sloan, Bi Xu
  • Humanized complement 5A receptor 1 antibodies and methods of use thereof
    Patent number: 11912781
    Abstract: The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.
    Type: Grant
    Filed: January 13, 2022
    Date of Patent: February 27, 2024
    Assignee: Visterra, Inc.
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver, Lauren Olinski
  • Antibody molecule-drug conjugates and uses thereof
    Patent number: 11890319
    Abstract: Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: February 6, 2024
    Assignee: VISTERRA, INC.
    Inventors: Zachary Shriver, Obadiah Joseph Plante, Kai Li, Karthik Viswanathan, James C. Delaney, Boopathy Ramakrishnan, Andrew M. Wollacott
  • Engineered polypeptides and uses thereof
    Patent number: 11858980
    Abstract: Polypeptides, such as antibody molecules and fusion proteins, comprising an Fc region, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: January 2, 2024
    Assignee: VISTERRA, INC.
    Inventors: Karthik Viswanathan, Boopathy Ramakrishnan, Brian Booth, Kristin Narayan, Andrew M. Wollacott
  • IMMUNOSILENCING Fc VARIANTS
    Publication number: 20230416372
    Abstract: The present disclosure provides, among other things Fc variants that have significantly reduced ADCC, ADCP and CDC function As described herein, the present disclosure is, in part based on identification of novel combinations of mutations that abolish binding to all Fc?RI, Fc?RIIa, Fc?RIIb, Fc?RIIIa, Fc?RIIb, and C1q.
    Type: Application
    Filed: August 29, 2023
    Publication date: December 28, 2023
    Applicant: VISTERRA, INC.
    Inventors: Karthik Viswanathan, Lauren Olinski, Ramki Ramakrishnan, Aditi Deshpande, Gregory Babcock, Zachary Shriver
  • Binding polypeptides and methods of making the same
    Patent number: 11820979
    Abstract: Polypeptides, such as antibody molecules and TCR molecules, and methods of making the same, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: November 21, 2023
    Assignee: VISTERRA, INC.
    Inventors: Zachary Shriver, Gregory Babcock, Luke Robinson
  • IMMUNOSILENCING Fc VARIANTS
    Publication number: 20230365694
    Abstract: The present disclosure provides, among other things Fc variants that have significantly reduced ADCC, ADCP and CDC function As described herein, the present disclosure is, in part based on identification of novel combinations of mutations that abolish binding to all Fc?RI, Fc?RIIa, Fc?RIIb, Fc?RIIIa, Fc?RIIIb, and C1q.
    Type: Application
    Filed: November 2, 2022
    Publication date: November 16, 2023
    Applicant: VISTERRA, INC.
    Inventor: Karthik VISWANATHAN
  • Antibody molecules to C5aR1 and uses thereof
    Patent number: 11773179
    Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: October 3, 2023
    Assignee: VISTERRA, INC.
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
  • Compositions and methods for treating and preventing influenza
    Patent number: 11230593
    Abstract: This disclosure relates to binding agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: January 25, 2022
    Assignee: VISTERRA, INC.
    Inventors: Kristin Narayan, Susan Sloan, Jill Yarbrough, David William Oldach, Zachary Shriver
  • Antibody molecule-drug conjugates and uses thereof
    Patent number: 11168131
    Abstract: Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: November 9, 2021
    Assignee: VISTERRA, INC.
    Inventors: Obadiah Joseph Plante, James C. Delaney, Karthik Viswanathan, Boopathy Ramakrishnan, Zachary Holmes Shriver, Andrew M. Wollacott
  • Methods of treating IgA nephropathy by administering an anti-APRIL (a proliferation-inducing ligand) antibody molecule
    Patent number: 11136385
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: October 5, 2021
    Assignee: VISTERRA, INC.
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • Antibody molecules to dengue virus and uses thereof
    Patent number: 11059883
    Abstract: Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: July 13, 2021
    Assignee: VISTERRA, INC.
    Inventors: Luke Robinson, Zachary Shriver, James R. Myette, Gregory Babcock, Karthik Viswanathan
  • Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (APRIL)
    Patent number: 10981982
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: April 20, 2021
    Assignee: VISTERRA, INC.
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • Antibody molecules to a proliferation-inducing ligand (APRIL)
    Patent number: 10968270
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: April 6, 2021
    Assignee: VISTERRA, INC.
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • Method of using anti-APRIL (a proliferation-inducing ligand) antibodies to reduce IGA
    Patent number: 10954296
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: March 23, 2021
    Assignee: VISTERRA, INC.
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • Method of using anti-APRIL (a proliferation-inducing ligand) antibodies to reduce IGA
    Patent number: 10919960
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: February 16, 2021
    Assignee: VISTERRA, INC.
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • HA binding agents
    Patent number: 10800835
    Abstract: This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: October 13, 2020
    Assignee: VISTERRA, INC.
    Inventors: Zachary Shriver, Karthik Viswanathan, Vidya Subramanian, Sasisekharan Raguram